Skip to content
10-Q

Quarterly Report

Phathom Pharmaceuticals, Inc. PHAT

0001193125-26-193946

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 79.76M sh
Shares Diluted Q1 2026 · Mar 31, 2026 82.05M sh
Shares Diluted Q1 2026 · Mar 31, 2025 71.97M sh
Capex Q1 2026 · Mar 31, 2026 $61K
Capex Q1 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$15.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$84.93M
Long Term Debt Q1 2026 · Mar 31, 2026 $163.68M
Long Term Debt Q1 2026 · Dec 31, 2025 $209.09M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Short Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $180.9M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $129.97M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$336.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$438.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$338.38M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$253.58M
Current Liabilities Q1 2026 · Mar 31, 2026 $125.04M
Current Liabilities Q1 2026 · Dec 31, 2025 $132.04M
Total Liabilities Q1 2026 · Mar 31, 2026 $642.08M
Total Liabilities Q1 2026 · Dec 31, 2025 $697.32M
Current Assets Q1 2026 · Mar 31, 2026 $276.57M
Current Assets Q1 2026 · Dec 31, 2025 $228.97M
Total Assets Q1 2026 · Mar 31, 2026 $305.12M
Total Assets Q1 2026 · Dec 31, 2025 $259.15M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.37
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.31
Eps Basic Q1 2026 · Mar 31, 2026 −$0.37
Eps Basic Q1 2026 · Mar 31, 2025 −$1.31
Sga Expense Q1 2026 · Mar 31, 2026 $54.01M
Sga Expense Q1 2026 · Mar 31, 2025 $94.47M
Rd Expense Q1 2026 · Mar 31, 2026 $7.77M
Rd Expense Q1 2026 · Mar 31, 2025 $9.18M
Net Income Q1 2026 · Mar 31, 2026 −$30.37M
Net Income Q1 2026 · Mar 31, 2025 −$94.32M
Operating Income Q1 2026 · Mar 31, 2026 −$15.48M
Operating Income Q1 2026 · Mar 31, 2025 −$78.86M
Gross Profit Q1 2026 · Mar 31, 2026 $46.31M
Gross Profit Q1 2026 · Mar 31, 2025 $24.8M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $12M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $3.72M
Revenue Q1 2026 · Mar 31, 2026 $58.3M
Revenue Q1 2026 · Mar 31, 2025 $28.52M